走进兰州，可以感受到这座老工业城市在嬗变。 一些企业家说，以前"跑断腿"的事，现在有政府专班人员在帮着跑，企业只专心做好生产经营；有科研 人员感慨，以前很多成果写完论文、评完奖就被束之高阁，现在转化的渠道更通畅了；有的干部坦言， 以前碰见棘手问题绕着走，现在不怕事、敢担事，还要琢磨如何干成事…… 这些心声被总结为一句话："当前的兰州呈现态势更好、气势更足、趋势更向上的发展势头。""十四 五"期间，特别是甘肃实施"强省会"行动以来的相关数据印证"兰州向上"—— 全市经济增速由2022年的0.8%提升至2025年的5.5%，对全省经济增长的贡献率由5.2%提升至27.7%；5 年来累计实施投资项目3270个，省外招商引资项目到位资金年均增长13%；综合科技进步水平指数达到 82.61%，跃居全球科研城市百强榜第48位；连续3年入选全国营商环境创新城市，连续4年居甘肃省营 商环境考评第一位。 近年来，兰州将营商环境视为"生命线"。甘肃省委常委、兰州市委书记张晓强说，对标国际国内一流水 平，兰州向高标准看齐，坚决打好优化营商环境攻坚战，着力营造良好产业发展生态和创业创新生态， 为推动高质量发展带来了新气象、新活力、新 ...

Core Viewpoint - Anxu Bio (688075) has disclosed its 2025 performance forecast, expecting a significant decline in net profit and a delay in its fundraising project until 2027 [1] Financial Performance - The company anticipates a net profit attributable to shareholders of 71 million to 85 million yuan, representing a year-on-year decrease of 55.80% to 63.08% [2] - The expected non-recurring net profit is projected to be between 13 million and 15.6 million yuan, reflecting a year-on-year decline of 58.84% to 65.70% [2] - The performance decline is primarily attributed to increased tariffs in the U.S. leading to reduced orders, foreign exchange losses due to currency fluctuations, decreased interest income, and asset depreciation [2] Project Progress - The company announced on January 30, 2026, that the completion date for its "in vitro diagnostic reagents and diagnostic instruments R&D and production project" has been postponed from January 2026 to January 2027 [3] - The delay is attributed to the impact of global respiratory infectious diseases on renovation progress and delays in equipment investment [3] Company Status - Shareholder Ma Huaxiang reduced his stake in the company by selling 804,500 shares between January 6 and January 21, 2026, decreasing his holding from 11.62% to 10.99%, which has reached the 1% threshold for equity change [4] Business and Technical Development - The company is actively transitioning from a single product focus to a comprehensive health management approach, including the expansion of pet testing products and chronic disease management apps [5] - The company is deepening its overseas market presence, with multiple international certifications expected in 2025, although related investments may lead to increased short-term expenses [5]

Core Viewpoint - The strategic cooperation agreement between China National Pharmaceutical Group (中生北控生物科技) and Guangdong Xiaoshou Medical Technology aims to enhance grassroots medical services and resource allocation in China [1] Group 1: Company Overview - China National Pharmaceutical Group is a leading supplier of in vitro diagnostic reagents, engaged in the research, production, sales, and distribution of diagnostic products [1] - The company provides reliable disease testing reagents to hospitals and healthcare institutions, emphasizing quality and reliability in its offerings [1] Group 2: Partnership Details - The partnership with Xiaoshou Medical focuses on multi-dimensional collaboration in the grassroots medical field, aiming to improve the operational efficiency and accessibility of medical services [1] - Xiaoshou Medical is a digital service provider for grassroots healthcare in China, having established partnerships with thousands of grassroots medical institutions across the country [1] - The collaboration is expected to integrate the company's R&D capabilities with Xiaoshou Medical's digital channel resources, facilitating the penetration of products and services into grassroots medical institutions [1] Group 3: Strategic Alignment - This strategic cooperation aligns with national initiatives to enhance the grassroots healthcare system and supports the "Healthy China" strategy [1]

Core Viewpoint - The strategic cooperation agreement between China National Pharmaceutical Group's subsidiary, Zhongsheng Beikong Biotechnology, and Xiaoshou Medical aims to enhance grassroots medical services and resource allocation in China [1] Group 1: Strategic Cooperation - The agreement was signed on February 11, 2026, in Beijing, focusing on multi-dimensional collaboration in the grassroots medical field [1] - Xiaoshou Medical is a digital service provider for grassroots healthcare in China, connecting and empowering medical institutions through technology [1] - The partnership is expected to integrate quality R&D capabilities with digital channel resources, accelerating the penetration of products and services into grassroots medical institutions [1] Group 2: Company Background - Zhongsheng Beikong Biotechnology is a leading supplier of in vitro diagnostic reagents in China, engaged in R&D, production, sales, and distribution of diagnostic products [1] - The company provides reliable disease testing reagents to hospitals and healthcare institutions, aligning with national strategies for improving grassroots healthcare systems and the "Healthy China" initiative [1] Group 3: Xiaoshou Medical's Role - Xiaoshou Medical has established partnerships with thousands of grassroots medical institutions across all provinces in China [1] - The company has developed an AI digital platform that integrates medical institution information systems, serving as a core "connector" to enhance operational efficiency and accessibility of grassroots medical services [1]

2026年伊始，长三角铁路建设交出亮眼"成绩单"。截至2025年底，区域铁路营业里程突破1.54万公里， 其中高铁里程攀升至8100余公里。作为长三角轨道交通网络的关键一环，沪苏湖高铁开通一周年以来， 累计安全运送旅客超3360万人次，日行列车从最初80对增至111.5对。这条将上海与湖州通行时间压缩 至半小时的"黄金走廊"，不仅让"工作在上海，生活在湖州"的同城化图景照进现实，更打通了研发实验 室与工厂生产线的"极速对流"通道。 就在这个月，沪苏浙皖四地同步亮出产业转型"施工图"：上海印发《支持先进制造业转型升级三年行动 方案（2026-2028年）》，苏、浙、皖则分别实施"人工智能+"行动、未来产业"星火计划"和智能机器人 专项。轨道交通的物理连接，正将四地政策规划焊接成一张紧密的产业协同网。 这种"时间折叠"效应，对于从实验室"0到1"走向生产线"1到10"的成果转化尤为关键。工艺参数的着 陆、试制的反复迭代、质量问题的现场闭环，绝非简单的图纸交接，而是充满了不确定性。视频会议或 许能高效传递信息，但永远无法替代研发专家与一线技工在产线的机器轰鸣声中的"即时碰撞"，当场解 决问题的"在场感"。 当"必须 ...

Group 1: 2025 Annual Performance Forecast - The company expects a net profit attributable to shareholders of 71 million to 85 million yuan for 2025, a decrease of 10,729.53 million to 12,129.53 million yuan compared to the previous year, representing a year-on-year decline of 55.80% to 63.08% [1] - The forecasted net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be between 13 million and 15.6 million yuan, a decrease of 2,229.79 million to 2,489.79 million yuan compared to the previous year, reflecting a year-on-year decline of 58.84% to 65.70% [1] Group 2: Previous Year Performance - In the previous year, the total profit was 21,064.01 million yuan, with a net profit attributable to shareholders of 19,229.53 million yuan and a net profit after deducting non-recurring gains and losses of 3,789.79 million yuan [2] Group 3: Reasons for Performance Changes - The company's main business remains stable, but increased strategic investments in new technology platforms and expansion in domestic and international markets have led to higher costs. Additionally, U.S. tariffs have reduced orders in certain regions, contributing to increased operating costs and a decline in profits due to exchange rate fluctuations, reduced interest income, and asset depreciation [4] Group 4: Fundraising Project Delay - The company has decided to postpone the completion date of the "in vitro diagnostic reagents and diagnostic instruments R&D and production project" from January 2026 to January 2027, without changing the investment content or total amount [9][10] - The delay is due to construction progress being slowed by global respiratory infectious diseases, affecting internal and external renovations, and the need for further payments related to the project [11][12] - The postponement is a prudent decision based on the actual situation of the project and will not adversely affect the company's normal operations or long-term development plans [12]

中证智能财讯硕世生物（688399）1月30日晚间披露2025年度业绩预告，预计2025年归母净利润亏损2940万元至4400万元，上年同期亏损200.17万元；扣非 净利润亏损8190万元至1.23亿元，上年同期亏损7183.71万元。以最新收盘价计算，市净率（LF）约2.03倍，市销率（TTM）约17.79倍。 以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 近年来市盈率变化情况（倍） 150 116.17 50 1883 0 2 82 - 50 - 100 -15 -200 -250 2022-06-30 ' 2021-12-37 2021-06-30 ' 2022-12-37 0-12-37 3-06-30 13-12-3- 2n- -○- 公司 -○- 行业均值 100 94,52 ହ 90 80 70 67o87 60 57:88 50 4476 40 30 26:05 20 10 d to #37 0 2027-12-37 | 2020-12-37 1 2022-12-37 3-06-30 ' 3-12-37 . 7-06-30 , 2022-06-30 ' 2n- ） 制图数 ...

Core Insights - Mingde Biological has initiated two equity acquisitions to focus on emergency rescue and in vitro diagnostic instruments, driven by declining COVID-19 testing business and increasing competition in the in vitro diagnostic industry [1][6] Group 1: Acquisition Details - On December 31, 2025, Mingde Biological signed a framework agreement with Blue Sail Medical to acquire 100% of Wuhan Bikaier Rescue Supplies Co., Ltd. for cash [2] - Wuhan Bikaier, a leader in emergency rescue, reported a revenue of 165 million yuan and a net profit of 13.87 million yuan in 2024, with a revenue of 75.8 million yuan and a net profit of 7.52 million yuan in the first half of 2025 [2] - The acquisition aims to enhance Mingde Biological's market position in critical care by integrating emergency protection services into industrial and household scenarios [2] Group 2: Second Acquisition - On January 20, 2026, Mingde Biological announced a plan to acquire 51% of Hunan Lanyi Medical Equipment Co., Ltd. for a total price of 35.71 million yuan, making it a subsidiary [3][4] - Hunan Lanyi focuses on IVD instruments and has significant potential in the market, particularly in glycosylated hemoglobin testing [4] - The acquisition includes performance commitments, with Hunan Lanyi required to achieve an average net profit of at least 20 million yuan over three years to trigger further acquisition phases [5] Group 3: Financial Performance - Mingde Biological's revenue has faced significant declines, with 2023 and 2024 revenues at approximately 750 million yuan and 350 million yuan, representing year-on-year declines of 92.88% and 53.30% respectively [6] - The company reported a net profit of approximately 74.93 million yuan in 2023, down 9.22% year-on-year, and a net profit of about 74.52 million yuan in 2024, down 0.54% year-on-year [6] - As of September 30, 2025, the company's cash reserves were 184 million yuan, a decrease of 63% from the beginning of the period [6]

（来源：中国市场监管报） 转自：中国市场监管报 本报讯 近年来，面对医疗器械产业发展新形势、企业成长新诉求，江苏省太仓市市场监管局主动前移 服务端口，持续优化服务举措，用精准高效的服务举措破解医疗器械产业发展难题，为医疗器械产业发 展保驾护航。 "太感谢你们了，帮我们啃下'硬骨头'，让项目顺利落地。"日前，苏州新波生物技术有限公司负责人曹 佳飞带着锦旗，专程来到太仓市市场监管局表达谢意。2025年，该企业启动体外诊断试剂进口转国产项 目，210个产品需要完成备案才能推进本土化生产。但时间紧、任务重，加上中美关税政策调整的影 响，企业项目推进陷入困境。得知诉求后，该局第一时间响应，迅速指派专人全程对接，精准指导企业 填报材料、规避风险，同时优化内部审核流程，联动苏州市市场监管局打通跨层级审批堵点。最终仅用 两个月便完成全部产品备案任务，为企业争取了宝贵的投产时间。项目落地后，企业预计每年新增产值 2000万元。 聚焦服务企业，联合省药监局审评中心、省药监局审评核查苏州分中心开展企业专项服务26家次，审评 审批工作进一步提质增效。建设省药监局审评中心远程咨询服务点，提供注册申报前期指导、技术难题 解答、审评进度查 ...

Core Insights - Suzhou's manufacturing sector is robust, with a leading number of global lighthouse factories and national-level 5G factories, indicating a strong industrial foundation and a high level of integration between information technology and industrialization [1][2] - The government work report emphasizes strengthening the real economy and building a modern industrial system as key priorities for 2026, focusing on enhancing competitive advantages in industrial clusters and promoting smart manufacturing [1][2] Group 1: Industrial Clusters and Economic Foundation - Suzhou has developed three trillion-level industries: electronic information, equipment manufacturing, and new materials, with manufacturing value added consistently accounting for over 40% of GDP [2] - The city aims to advance its industrial clusters towards higher value chains, particularly in biomedicine, electronic information, and new energy sectors, while also promoting the establishment of over 3,500 smart factories [2][3] Group 2: AI Integration in Manufacturing - Artificial intelligence is positioned as a key driver for upgrading Suzhou's manufacturing, with over 3,000 AI-related companies and initiatives to integrate AI into manufacturing processes [3][4] - The government is focusing on high-end chips, algorithms, and intelligent equipment innovation, with the local robot industry valued at over 160 billion yuan, accounting for one-seventh of national production [4] Group 3: Modern Service Industry Development - The modern service industry is seen as essential for supporting industrial growth, with plans to enhance the quality and capacity of production services, targeting an 8% revenue growth by 2026 [5] - Proposals include providing comprehensive services such as consulting and training to facilitate the upgrade of small and medium enterprises through collaborative platforms [5][6] Group 4: Talent Development - Talent is identified as a critical factor for industrial upgrading, with a strong demand for engineers and skilled technicians capable of addressing complex engineering challenges [6] - Suggestions include establishing specialized programs in universities to align educational outcomes with industry needs, ensuring a continuous supply of practical talent for industrial development [6]